This combined method shows promise as a successful treatment option for patients with glioblastoma and lung cancer with various EGFR mutations, including those who have developed resistance to osimertinib in Non-Small Cell Lung Cancer (NSCLC) (Ko et al. 2021). This evidence concerns the gene EGFR and lung cancer.